RESUMO
INTRODUCTION: The pace of innovation has accelerated in virtually every area of tau research in just the past few years. METHODS: In February 2022, leading international tau experts convened to share selected highlights of this work during Tau 2022, the second international tau conference co-organized and co-sponsored by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation. RESULTS: Representing academia, industry, and the philanthropic sector, presenters joined more than 1700 registered attendees from 59 countries, spanning six continents, to share recent advances and exciting new directions in tau research. DISCUSSION: The virtual meeting provided an opportunity to foster cross-sector collaboration and partnerships as well as a forum for updating colleagues on research-advancing tools and programs that are steadily moving the field forward.
Assuntos
Doença de Alzheimer , Tauopatias , Humanos , Proteínas tauRESUMO
INTRODUCTION: At the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias. METHODS: The meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry. RESULTS: During the 4-day meeting, presenters illuminated aspects of the cross-talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]). DISCUSSION: This manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Assuntos
Doença de Alzheimer , Humanos , Doença de Alzheimer/patologia , Microglia/patologia , Inflamação , Apolipoproteínas E/genéticaRESUMO
Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.
Assuntos
Doença de Alzheimer , Disfunção Cognitiva , Biomarcadores , Descoberta de Drogas , Humanos , Proteínas tauRESUMO
Alzheimer's disease (AD) and all other dementia represent a global challenge, with an estimated 50 million individuals in the world living with dementia today. In low and middle income countries (LMICs), the burden of disease often is greater, and some of these countries are projected to have some of the largest increases in dementia prevalence during the next few decades. As the world's largest voluntary health organization dedicated to AD and all other dementia, the Alzheimer's Association is committed to its vision of a world without dementia and recognizes the needs, challenges, and opportunities for dementia research in all parts of the world, and especially in LMICs. Currently, the Association is devoting more than $215 million in funding to nearly 600 best-of-field projects in 31 countries, including a significant number of projects that advance and support LMIC-specific research. The innovative work in LMICs is focused on addressing unmet needs or challenges associated with the many unique cultural, demographic, and economic characteristics of these countries. The Association also is expanding leading global forums such as the Alzheimer's Association International Conference (AAIC). In an effort to create new learning and participation opportunities, the Association also has been partnering with other international organizations and collaborating with local leadership to provide AAIC Satellite Symposia (AAIC SS) in LMIC regions around the world. In 2021 and beyond, the Association is committed to continuing these LMIC-focused initiatives, identifying gaps in LMIC research and resources, and enhancing collaboration and communication among researchers in these regions.
RESUMO
The study of Alzheimer's disease (AD) has led to an increased understanding of the multiple pathologies and pathways of the disease. As such, it has been proposed that AD and its various stages might be most effectively treated with a combination approach rather than a single therapy; however, combination approaches present many challenges that include limitations of non-clinical models, complexity of clinical trial design, and unclear regulatory requirements. The Alzheimer's Association Research Roundtable meeting on May 7-8, 2018, discussed the approaches and challenges of combination therapy for AD. Experts in the field (academia, industry, and government) provided perspectives that may help establish a path forward for the development of new combination therapies.
RESUMO
This in-depth article on the sixth leading cause of death in the U.S. reports on the optimism of cutting-edge leaders in Alzheimer's disease research. The author examines key considerations such as the status of biomarker tests, and the search for new biomarkers; securing an accurate definition of the disease; risk factors; clinical trials and non-pharmacological studies.
RESUMO
New sleep deprivation studies confirm the relationship between inadequate sleep and a wide range of disorders, such as hypertension, obesity and type-2 diabetes, cardiovascular disease, impaired immune functioning, and more.
RESUMO
Although a significant increase in life expectancy for people with human immunodeficiency virus was reported last spring, experts in the U.S. caution that the results are not a cause for complacency. Efforts to develop a vaccine and a cure remain essential, as do efforts to develop interventions that may improve adherence.
RESUMO
In advance of the new guidelines being published this year, the author discusses treatment targets, diagnostics, and public policy with three hypertension experts.
RESUMO
More than four years after the release of a landmark report by the Institute of Medicine focused attention on pain in America, there are encouraging signs that the nation may be poised to undergo the "cultural transformation" advocated by the report.
Assuntos
Detecção Precoce de Câncer , Neoplasias Pulmonares/diagnóstico por imagem , Análise Custo-Benefício , Detecção Precoce de Câncer/economia , Detecção Precoce de Câncer/métodos , Humanos , Cobertura do Seguro , Seguro Saúde , Programas de Rastreamento , Doses de Radiação , Tomografia Computadorizada por Raios X , Estados UnidosRESUMO
With disease-modifying treatments available for relapsing-remitting multiple sclerosis (MS), the quest for therapies for progressive MS has become a key focus of research.
RESUMO
Lung cancer treatment has undergone significant change in the past decade, leading to remarkable growth in the number and variety of therapeutic options. This shift reflects, in part, a significant refinement in the molecular categorization of lung cancer.
RESUMO
Developing a disease-modifying treatment for Alzheimer's disease has stymied researchers. A collaborative re-examination of premises that guided disappointing earlier trials is under way, with talk of new targets and combination therapies.
RESUMO
For so long, multiple sclerosis has frustrated physicians and patients. With bold new treatments on the way, payers are thinking about tighter management. Formal treatment guidelines would help. Bio-markers could also sort out the 'right-drug, right-patient' conundrum.